AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11191179
Drug: Flumazenil 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 2.5 mg
Trial: 11191179
Drug: Flumazenil 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 5.0 mg
Trial: 11191179
Drug: Flumazenil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (all doses)
Trial: 3095507
Drug: Empirical mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empirical mannitol therapy irrespective of ICP readings
Trial: 29332056
Drug: Percutaneous ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous ozone injection alone (Control)
Trial: 29332056
Drug: Combined ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ozone injection and percutaneous microdiscectomy (Treatment)
Trial: 27476806
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable second-generation antipsychotic
Trial: 27476806
Drug: Oral second-generation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral second-generation antipsychotic
Trial: 27476806
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable medication administration schedule
Trial: 22324458
Drug: Standardized assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized assessment and evidence-based treatment for urinary incontinence
Trial: 20399995
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation A (valsartan 160 mg)
Trial: 20399995
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation B (valsartan 160 mg)
Trial: 20399995
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (valsartan 160 mg)
Trial: 18512043
Drug: Euglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (blood glucose level at 5 mmol/l)
Trial: 18512043
Drug: Hyperglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (blood glucose level at 11 mmol/l)
Trial: 17310949
Drug: DNAase treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNAase treatment
Trial: 14671698
Drug: Contrast-enhanced duplex
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced duplex ultrasound (Definity, infused at 2 to 4 mL/min)
Trial: 9179187
Drug: Androgen ablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen ablation therapy (AAT)
Trial: 9179187
Drug: No androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No androgen ablation therapy (no AAT)
Trial: 1350140
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon alpha 2a plus cryotherapy
Trial: 2859970
Drug: Terbutaline, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline, 0.5 mg intravenously
Trial: 2859970
Drug: Prenalterol, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol, 1.0 and 4.0 mg intravenously
Trial: 28535438
Drug: Edoxaban 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 90 mg
Trial: 28535438
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg in sodium citrate tubes
Trial: 28535438
Drug: Edoxaban 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 90 mg in sodium citrate tubes
Trial: 25732165
Drug: Cytarabine 200
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 200 mg/m2 continuous IV infusion once per day on days 1 to 7 plus amonafide 600 mg/m2 IV over 4 hours on days 1 to 5 (A + C arm)
Trial: 25732165
Drug: Cytarabine 200
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 200 mg/m2 continuous IV infusion once per day on days 1 to 7 plus daunorubicin 45 mg/m2 IV over 30 minutes once per day on days 1 to 3 (D + C arm)
Trial: 21790765
Drug: N-butylscopolammonium bromide
RxNorm normalized name: N-butylscopolammonium
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-butylscopolammonium bromide (NBB) 0.3 mg/kg bwt i.v.
Trial: 21790765
Drug: Xylazine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine 0.25 mg/kg bwt i.v.
Trial: 21790765
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NBB (0.3 mg/kg bwt) and xylazine (0.25 mg/kg bwt) i.v.
Trial: 19561254
Drug: US-guided percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided percutaneous treatment
Trial: 16756418
Drug: Medication contingency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication contingency group
Trial: 8222516
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion (0.015 to 0.075 microgram min‐1 kg‐1) during euhydration
Trial: 8222516
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion (0.015 to 0.075 microgram min‐1 kg‐1) during overhydration
Trial: 2939869
Drug: Doxazosin 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 16 mg daily
Trial: 26255249
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) monotherapy
Trial: 21497708
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (200 mL twice daily for 2 weeks)
Trial: 17133780
Drug: Nourkrin (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nourkrin (active preparation)
Trial: 29866011
Drug: Triflusal 300
RxNorm normalized name: triflusal 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal 300 mg twice daily or 600 mg once daily
Trial: 20199764
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV-23)
Trial: 18043484
Drug: 800‐mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800‐mg oral dose of EGCG administered as Polyphenon E under fasting conditions
Trial: 18043484
Drug: 800‐mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800‐mg oral dose of EGCG administered as Polyphenon E under fed conditions
Trial: 16251628
Drug: Supplementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation of breast‐feeding mothers with 60 mg retinol equivalent (RE) vitamin A within 4 wk of delivery
Trial: 16251628
Drug: EPI‐linked supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI‐linked supplementation of infants with 7.5 mg RE vitamin A at 6, 10, and 14 wk
Trial: 1758201
Drug: terbutaline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline 0.5 mg inhaled through a cone spacer with positive expiratory pressure (+PEP)
Trial: 1758201
Drug: terbutaline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline 0.5 mg inhaled through a cone spacer without positive expiratory pressure (‐PEP)
Trial: 7093597
Drug: Oral amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amitriptyline (75-225 mg/day)
Trial: 7093597
Drug: Intramuscular flupenthixol
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular flupenthixol decanoate (10-30 mg every 14 days)
Trial: 31526640
Drug: New domestic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New domestic dacron patch
Trial: 31526640
Drug: Imported cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported cardiac polyester patch
Trial: 28838955
Drug: Bosutinib 200
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 200 mg/d
Trial: 28838955
Drug: Pooled bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pooled bosutinib (200 mg/d and 400 mg/d)
Trial: 24830824
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant 0.7 mg (DEX implant)
Trial: 19736426
Drug: Dexamethasone-cyclophosphamide pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide (DCP+C)
Trial: 19736426
Drug: Cyclophosphamide pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide pulse and daily oral prednisolone (CP+P)
Trial: 10923750
Drug: Zotepine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine (300 mg daily, with fallback to 150 mg if necessary)
Trial: 1590226
Drug: Amiodarone 200
RxNorm normalized name: amiodarone 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 200 mg/day
Trial: 18479589
Drug: Chlorthalidone 6.25
RxNorm normalized name: Chlorthalidone 6.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 6.25 mg + Atenolol 25 mg
Trial: 18479589
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg + Amlodipine 2.5 mg
Trial: 11009045
Drug: Mefloquine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (500 mg, 250 mg, 250 mg over 12 h) followed by co-artemether (6 x 4 tablets over 60 h)
Trial: 1405960
Drug: Canal preparation
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canal preparation with Betadine and alcohol
Trial: 4057312
Drug: Haloperidol 5
RxNorm normalized name: haloperidol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5 mg IM
Trial: 24762109
Drug: Low-dose ethinyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ethinyl estradiol (EE2) during childhood (25 ng/kg/d for ages 5-8 years; 50 ng/kg/d for ages >8-12 years)
Trial: 19515367
Drug: Paroxetine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine administration for 5 weeks
Trial: 12450644
Drug: Buspirone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone combined with non-directive therapy
Trial: 12450644
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with non-directive therapy
Trial: 8769497
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (CPAP and AMP)
Trial: 30062946
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2.0 g of TXA orally two hours preoperatively (group A)
Trial: 30062946
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of TXA followed by 1.0 g orally three hours postoperatively (group B)
Trial: 30062946
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of TXA followed by 1.0 g three and nine hours postoperatively (group C)
Trial: 30062946
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of TXA followed by 1.0 g orally three, nine, and 15 hours postoperatively (group D)
Trial: 26230270
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day desvenlafaxine
Trial: 26230270
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day desvenlafaxine
Trial: 18413835
Drug: Doxercalciferol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxercalciferol (10 microg orally, days 1-28) with docetaxel (35 mg/m2 i.v., days 1, 8, and 15)
Trial: 18413835
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with docetaxel (35 mg/m2 i.v., days 1, 8, and 15)
Trial: 12950597
Drug: 3'SL 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3'SL 10 g/day
Trial: 12950597
Drug: 3'SL 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3'SL 20 g/day
Trial: 7572258
Drug: Moclobemide (MOC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (MOC; maximum dose 600 mg)
Trial: 7572258
Drug: Doxepin (DOX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (DOX; maximum dose 250 mg)
Trial: 7036171
Drug: Pulses of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulses of methylprednisolone, immunosuppressive drugs and anticoagulants plus plasma exchanges for one to two months (PE+)
Trial: 7036171
Drug: Pulses of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulses of methylprednisolone, immunosuppressive drugs and anticoagulants (Control)
Trial: 30549127
Drug: Carbamazepine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (single oral dose)
Trial: 30549127
Drug: Brivaracetam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam (single oral dose)
Trial: 30549127
Drug: Tiagabine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (single oral dose)
Trial: 26087567
Drug: Jintian'ge capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jintian'ge capsule in addition to percutaneous kyphoplasty (PKP)
Trial: 23579320
Drug: Control conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control conditions (acetaminophen and placebo)
Trial: 22384545
Drug: Danhong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danhong Injection (DHI) 20 mL intravenously dripped in 250 mL 0.9% sodium chloride injection from 2-3 days before PCI to 3 days after PCI, once daily.
Trial: 22384545
Drug: Routine medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine medicines including loperamide injection, enteric coated aspirin, Betaloc, and routine rehydration therapy (Control group).
Trial: 19455042
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at target plasma concentrations (0, 1.3, 1.7, 2.0, 2.4, 2.8 microg ml(‐1))
Trial: 16963215
Drug: Daily cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cannabis users (N=18)
Trial: 16963215
Drug: Non-daily cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-daily cannabis users (N=20)
Trial: 11168270
Drug: Implant-mucosa-borne overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-mucosa-borne overdenture on 2 IMZ implants (IMZ-group)
Trial: 11168270
Drug: Mainly implant-borne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly implant-borne overdenture retained by a transmandibular implant (TMI-group)
Trial: 9923572
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ASA plain
Trial: 9923572
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ASA enteric-coated
Trial: 9923572
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ASA plain
Trial: 2748718
Drug: Two cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycle ergometer exercise sessions and one bronchial hygiene treatment session per day (EX Group)
Trial: 2748718
Drug: Three bronchial
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three bronchial hygiene treatment sessions per day (PD Group)
Trial: 25453519
Drug: Therapeutic yoga
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic yoga (16 sessions, twice a week for 8 weeks)
Trial: 18829015
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human FSH plus hCG after GnRH agonist treatment
Trial: 17697815
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (aspirin, clopidogrel, and cilostazol)
Trial: 15530674
Drug: HB‐AS04 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB‐AS04 (2 doses at 0 and 6 months)
Trial: 15530674
Drug: Comparator vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator vaccine (3 doses at 0, 1, and 6 months)
Trial: 11586161
Drug: Low-intensity pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity pulsed ultrasound therapy (20-minute daily applications at the site of the nonunion)
Trial: 7924650
Drug: Retinamide II
RxNorm normalized name: retinamide
DrugBank: Retinamidic acid (DB17418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinamide II (RII) suppository intravaginally, once daily for 50 days
Trial: 7924650
Drug: Placebo, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily for 50 days
Trial: 4877801
Drug: Micronized flumedroxone
RxNorm normalized name: flumedroxone
DrugBank: Flumedroxone (DB13610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized flumedroxone 10 mg t.d.s.
Trial: 28195931
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication adherence
Trial: 26865198
Drug: Poor medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor medication adherence
Trial: 21947753
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 50 mg/kg bolus followed by 15 mg/kg/h infusion and another 50 mg/kg into the bypass circuit
Trial: 18649974
Drug: Intravenous glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glutamine dipeptide
Trial: 16824141
Drug: MPA pharmacokinetics
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA pharmacokinetics with tacrolimus
Trial: 9293933
Drug: Butyric acid
RxNorm normalized name: butyric acid
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butyric acid enemas (40 mmol) twice per day for two weeks
Trial: 7994793
Drug: Single instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single instillation of hydroxypropylcellulose-doxorubicin (20 mg/20 ml)
Trial: 3176836
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 0.5 mg/kg midazolam and 0.05 mg/kg atropine
Trial: 3176836
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 0.15 mg/kg midazolam and 0.02 mg/kg atropine
Trial: 24109189
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg + HCTZ 25 mg
Trial: 24109189
Drug: Bisoprolol 10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 10 mg + HCTZ 25 mg
Trial: 22074958
Drug: Chlorpromazine 100
RxNorm normalized name: chlorpromazine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 100 mg simple dose formulation
Trial: 18202711
Drug: Oblique injection
RxNorm normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oblique injection technique
Trial: 14606135
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) with factor V Leiden mutation
Trial: 10678615
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (2,000 microg daily)
Trial: 7687608
Drug: Histamine challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine challenge (1 mg)
Trial: 7687608
Drug: Allergen challenge
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen challenge (increasing doses)
Trial: 3307584
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human insulin (0.2 U/kg body weight)
Trial: 3307584
Drug: Purified pork
RxNorm normalized name: Insulin purified pork
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purified pork insulin (0.2 U/kg body weight)